ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2018
Angiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04467671 (Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.Medicine · 2019Trial
- Chronic kidney disease and stromal cell-derived factor 1α peptide-functionalization impact on polycarbonate-bisurea based in situ tissue-engineered vascular graft dynamics.Scientific reports · 2026Article
- Tissue Engineered Vascular Grafts: A Quarter Century Journey of Courage, Challenge, and Persistence.JACC. Basic to translational science · 2025Article
- Harnessing the potential of monocytes/macrophages to regenerate tissue-engineered vascular grafts.Cardiovascular research · 2024Review
- Hemodynamics and Wall Mechanics of Vascular Graft Failure.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Tissue Engineering of Vascular Grafts: A Case Report From Bench to Bedside and Back.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Implanted Tissue-Engineered Vascular Graft Cell Isolation with Single-Cell RNA Sequencing Analysis.Tissue engineering. Part C, Methods · 2023Article
- Immunomodulation Strategies for the Successful Regeneration of a Tissue-Engineered Vascular Graft.Advanced healthcare materials · 2022Review
- Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.Frontiers in bioengineering and biotechnology · 2022Review
- Review
- Electrospun Tissue-Engineered Arterial Graft Thickness Affects Long-Term Composition and Mechanics.Tissue engineering. Part A · 2021Article
- Tissue Engineered Vascular Graft Recipient Interleukin 10 Status Is Critical for Preventing Thrombosis.Advanced healthcare materials · 2020Article
- Proceedings From the 2019 Stanford Single Ventricle Scientific Summit: Advancing Science for Single Ventricle Patients: From Discovery to Clinical Applications.Journal of the American Heart Association · 2020Article
- Spontaneous reversal of stenosis in tissue-engineered vascular grafts.Science translational medicine · 2020Article
- Progressive Reinvention or Destination Lost? Half a Century of Cardiovascular Tissue Engineering.Frontiers in cardiovascular medicine · 2020Review
- The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care.Applied sciences (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
We previously developed a tissue-engineered vascular graft (TEVG) made by seeding autologous cells onto a biodegradable tubular scaffold, in an attempt to create a living vascular graft with growth potential for use in children undergoing congenital heart surgery. Results of our clinical trial showed that the TEVG possesses growth capacity but that its widespread clinical use is not yet advisable due to the high incidence of TEVG stenosis. In animal models, TEVG stenosis is caused by increased monocytic cell recruitment and its classic ("M1") activation. Here, we report on the source and regulation of these monocytes. TEVGs were implanted in wild-type, CCR2 knockout ( Ccr2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.